MiraVista Diagnostics is an Industry Leading Mycology Reference Laboratory
Clinical Laboratory Testing for Serious Fungal Infections
The company was founded in 2002 by the renowned infectious disease scientist, Dr. Lawrence Joseph Wheat, whose groundbreaking research contributions resulted in the development of the first histoplasmosis antigen test in 1986. Today, MiraVista Diagnostics serves the medical and healthcare sectors in the U.S. and Canada processing over 100,000 tests per year for fungal infections. This includes antigen and antibody detection tests for coccidioides (valley fever fungus), aspergillus, histoplasmosis capsulatum, Blastomyces dermatitidis and cryptococcus.
MiraVista Diagnostics offers same-day testing, prompt response, fast shipping and direct access to the laboratory’s team of experienced infectious disease specialists that has collectively published more than 1,000 scientific research articles. Clients include large medical research hospitals, healthcare systems and universities as well as large reference labs. Contact us to discuss a fungal infection case, set up a corporate account for high volume testing or order from among MiraVista Diagnostics’ menu of diagnostic screening tests for fungal diseases.
MiraVista Institutional Biosafety Committee (IBC) Announcement
In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure that MiraVista…
READ MORE →
Pulmonary Histoplasmosis: A Clinical Update – Published
MiraVista Diagnostics’ article “Pulmonary Histoplasmosis: A Clinical Update” has been published in “Journal of Fungi” as part of the Special Issue “Diagnosis and Treatment of Invasive Pulmonary Fungal Infections.” Read the article. View the PDF.
Diagnosis of Histoplasmosis Using the MVista Histoplasma Galactomannan Antigen Qualitative Lateral Flow–Based Immunoassay: A Multicenter Study.
The second US based multicenter study found high concordance with the MiraVista LFA and EIA and reported higher sensitivity with the EIA. Read more about the US LFA Multicenter Study.
Validation and Concordance Analysis of a New Lateral Flow Assay for Detection of Histoplasma Antigen in Urine
Several studies have recently been published, evaluated the MVista® CE marked Histoplasma urine antigen lateral flow immunoassay. The first study was conducted in Columbia in partnership with the CDC and reported high sensitivity with the MVD LFA. Read more about…
READ MORE →
MiraVista Institutional Biosafety Committee (IBC) Announcement
In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure that MiraVista…
READ MORE →
Test Report Updates for 2021
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative EIA. The new…
READ MORE →
